Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Macrophage Activation Syndrome

Alexei A. Grom, MD  |  Issue: December 2010  |  December 1, 2010

Figure 2: Role of the hemoglobin–haptoglobin scavenger receptor CD163, heme oxygenase, and ferritin in adaptation to oxidative stress induced by free heme and iron. Free heme is a source of redox-active iron. To prevent cell damage caused by iron-derived reactive oxygen species, haptoglobin forms a complex with free hemoglobin. The haptoglobin–hemoglobin (Hp–Hb) complexes then bind to CD163 and are internalized by the macrophage. Endocytosis of Hp–Hb complexes leads to upregulation of heme oxygenase (HO) enzymatic activity. HO degrades the heme subunit of Hb into biliverdin, which is subsequently converted to bilirubin, carbon monoxide, and free iron. The free iron is either sequestered in association with ferritin within the cell or transported and distributed to red blood cell precursors in the bone marrow. Increased uptake of Hp–Hb complexes by macrophages leads to increased synthesis of ferritin. Highly elevated levels of serum ferritin are an important diagnostic feature of both MAS and HLH.

Unfortunately, the application of the HLH diagnostic criteria to systemic JIA patients with suspected MAS is problematic. Some of the HLH markers such as lymphadenopathy, splenomegaly, and hyperferritinemia are common features of active SJIA itself and, therefore, do not distinguish MAS from a conventional SJIA flare. Other HLH criteria, such as cytopenias and hypofibrinogenemia, become evident only at the late stages. This is related to the fact that systemic JIA patients often have increased white blood cell and platelet counts as well as increased serum levels of fibrinogen as a part of the inflammatory response seen in this disease. Therefore, when these patients develop MAS, they may only reach the degree of cytopenias and hypofibrinogenemia seen in HLH at the late stages of the syndrome when their management becomes challenging. The application of criteria is even more problematic for the diagnosis of MAS in patients with SLE in whom autoimmune cytopenias are common and difficult to distinguish from those caused by MAS. In these patients, the presence of extreme hyperferritinemia and lactate dehydrogenase elevation should raise suspicion for MAS. Attempts to modify the HLH criteria to increase their sensitivity and specificity for the diagnosis of MAS in rheumatic conditions have been initiated.19

Differential Diagnosis

In addition to distinguishing MAS from a flare of an underlying rheumatologic disease, one must consider in differential diagnosis other clinical entities associated with hepatic dysfunction, coagulopathy, cytopenias, or encephalopathy. In some MAS patients, the combination of hepatic dysfunction with encephalopathy may be reminiscent of Reye syndrome. The diagnosis of Reye syndrome, however, is based of the presence of a viral prodrome, unexplained vomiting, behavioral changes, and a distinctive chemical profile characterized by rapid coordinated increase in serum aminotransferase levels, blood ammonia, and prothrombin time with relatively minimal changes in serum bilirubin. The DIC-like coagulopathy seen in MAS is not a feature of Reye syndrome. Conversely, a sharp increase in blood ammonia levels, an important feature of Reye syndrome, is usually very mild in MAS. The hemorrhagic syndrome seen in MAS may resemble thrombotic thrombocytopenic purpura. However, microangiopathic anemia with emergence of fragmented red blood cells in peripheral circulation, a central feature of thrombotic thrombocytopenic purpura, is usually not seen in MAS. It is also important to differentiate MAS from malignancy-associated HLH and malignant histiocytic disorders. Some other important differential diagnoses include sepsis and drug reactions.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Treatment

MAS is a life-threatening condition associated with high mortality rates. Therefore, early recognition and of this syndrome and immediate therapeutic intervention to produce a rapid response are critical. Most clinicians start with intraveneous methylprednisolone pulse therapy (30 mg/kg for three consecutive days) followed by 2–3 mg/kg/day in four divided doses. If a response to steroids is not evident within 24–48 hours, parenteral administration of cyclosporine A (CyA; 2–7 mg/kg/day) should be initiated.1,4,20 Patients in whom MAS remains active despite the use of corticosteroids and CyA present a serious challenge. In these patients, one might consider using the HLH-2004 treatment protocol developed by the International Histiocyte Society (see Table 1, p. 23). In addition to steroids and CyA, this protocol also includes etoposide (or VP16), a podophyllatoxin derivative that inhibits DNA synthesis by forming a complex with topoisomerease II and DNA. However, potential toxicity of the drug including severe myelosuppression is a major concern, particularly in patients with hepatic impairment. Etoposide is metabolized by the liver and then both the unchanged drug and its metabolites are excreted through the kidneys. Because patients who may require the use of etoposide are very likely to have hepatic and renal involvement, caution should be exercised to properly adjust the dosage and thus limit the extent of potential side effects such as severe bone marrow suppression,which may be detrimental. Reports describing deaths caused by severe bone marrow suppression and overwhelming infection have been published.

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditions Tagged with:Diagnostic CriteriaGuidelinesmacrophage activation syndromeMASPathogenesisTreatment

Related Articles
    Fellows' Forum Case Report: Hemophagocytic Lymphohistiocytosis

    Fellows’ Forum Case Report: Hemophagocytic Lymphohistiocytosis

    August 13, 2017

    The patient was a 48-year-old woman who saw her primary care physician for a flu-like illness three months prior to admission. Her symptoms initially improved, but recurred one month later; she was treated symptomatically, and again symptoms resolved. Two months later, she presented to an outside facility’s emergency department with fever to 103ºF, with associated…

    Diagnosing & Treating Hemophagocytic Lymphohistiocytosis in Adults

    June 15, 2020

    Primary hemophagocytic lymphohistiocytosis (HLH) is caused by genetic mutations and inherited syndromes; it therefore occurs in the pediatric age group. Secondary HLH, however, is more common in adults and is often triggered by other disease states, such as malignancies, chronic immuno­suppression, infections and autoimmune disease.1,2 Macrophage activation syndrome (MAS) is a subset of secondary HLH…

    Ebola: Hemorrhagic Fever and Macrophage Activation Syndrome

    December 1, 2014

    Rheumatologists focus on similar clinical, laboratory findings to better
    understand pathobiology of Ebola infection

    For MAS, Early Diagnosis Is Key

    November 1, 2010

    Research helps hasten diagnosis and treatment of macrophage activation syndrome

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences